GLP1 Benefits by Clinical Trials
GLP-1 Agonists and Pancreatitis Risk: Reassessing an Old Concern with New Evidence
Modern data confirm GLP-1 agonists are not linked to pancreatitis. Studies from 2025 show no increase in risk and, in some cases, lower recurrence rates and mortality. These findings overturn old concerns and highlight how improved metabolic control may protect the pancreas. Clinicians can now use GLP-1s more confidently as part of holistic, individualized care for diabetes and obesity.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Insights from Dr. Tashko, Pancreas Health
CagriSema in Clinical Trials: What Patients Should Know
Two NEJM trials highlight CagriSema, a combination of cagrilintide and semaglutide, as a promising investigational therapy. Patients experienced weight loss exceeding semaglutide alone, with results comparable to tirzepatide. While not FDA approved, the research suggests CagriSema may offer a future option for obesity and diabetes management.
Published
How GLP-1 Receptor Agonists Benefit Kidney and Heart Health
GLP-1 receptor agonists have transformed type 2 diabetes care. They lower blood sugar, reduce cardiovascular risks, and now show promise for kidney health. A recent Lancet meta-analysis highlights these benefits, offering insights into how these medications can protect vital organs.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Heart Health, Kidney Health
SURMOUNT-1 Trial: Tirzepatide for Treating Obesity and Preventing Diabetes
Tirzepatide has emerged as a game-changing treatment for obesity and diabetes prevention. This three-year study, an extension of the SURMOUNT-1 trial, highlights its ability to deliver sustained weight loss and significantly lower the risk of type 2 diabetes in individuals with both obesity and prediabetes.
Published
SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Patients with Obesity
The SUMMIT trial investigated how tirzepatide (Mounjaro or Zepbound), a weight-loss medication, affects heart failure with preserved ejection fraction (HFpEF) in patients with obesity. HFpEF, where the heart pumps effectively but struggles to fill properly, is more common in individuals with high body mass index (BMI). Researchers aimed to determine whether tirzepatide could improve cardiovascular outcomes and enhance quality of life for this population.
Published
Can GLP-1s, Semaglutide and Liraglutide Treat Alcohol Use Disorder?
Alcohol Use Disorder (AUD) remains a major global health issue. While psychosocial treatments dominate, medications play a lesser role. Exciting new findings suggest GLP-1 agonists, primarily used for type 2 diabetes and obesity, may help. Among these, semaglutide and liraglutide show the strongest potential for reducing alcohol-related hospitalizations. Though promising, further research is necessary to confirm these results.
Published
Retatrutide: A Promising Breakthrough for Fatty Liver Disease
Fatty liver disease has become a global health crisis, affecting millions worldwide. Now called metabolic dysfunction-associated steatotic liver disease (MASLD), its prevalence has skyrocketed due to rising obesity rates. Retatrutide, a triple hormone receptor agonist, is showing a game-changing potential in reducing liver fat and improving metabolic health.
Published
GLP-1: A Surprising Friend Against Cancer in Type 2 Diabetes?
New research suggests diabetes drugs known as GLP-1 receptor agonists (GLP-1) might protect against certain cancers. This study focused on type 2 diabetes patients and followed them for 15 years. It’s a surprising finding that could change cancer prevention for diabetes patients.
Published
Semaglutide’s Double Power for Weight Loss and Knee Pain
The study, Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis, explores the impact of weekly semaglutide injections. It focuses on weight loss and pain relief for people with obesity and knee osteoarthritis (OA)
Published
Breaking New Ground: Liraglutide Offers Hope for Childhood Obesity in Kids Under 12
The SCALE Kids study showed that liraglutide helped children aged 6 to under 12 with obesity reduce their BMI when combined with lifestyle changes like better eating and more exercise. Children taking liraglutide had better results than those who took a placebo, with many achieving meaningful weight loss.
Published
Categorized as Child Health, Dr. Tashko’s Key Clinical Trials, Drug Information, GLP1 agonist, Obesity Care
Tirzepatide: A Dual Solution for Obstructive Sleep Apnea and Obesity
Obstructive sleep apnea (OSA) is characterized by disordered breathing during sleep and is associated with significant cardiovascular complications. Excess body fat, or adiposity, is a primary risk factor for OSA. The SURMOUNT study explores the potential of tirzepatide (branded as Mounjaro or Zepbound) as a treatment for OSA in obese individuals through two phase 3, double-blind, randomized, controlled trials.
Published
The SYNERGY Study on Tirzepatide: A Game-Changer for MASH Treatment
Metabolic dysfunction–associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH), is a severe liver disease. MASH involves fat buildup, liver inflammation, and cell injury, often leading to fibrosis. With rising obesity and type 2 diabetes, MASH cases are growing globally.
Published